Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cullinan Therapeutics is a biopharmaceutical company focused on developing targeted immunology and oncology therapies. Its pipeline includes clinical-stage candidates like CLN-978 for autoimmune diseases, and CLN-619, CLN-049, and CLN-617 for various cancers. The company leverages innovative biologics, collaborates with partners, and holds extensive intellectual property rights to address unmet medical needs in autoimmune disorders and cancer markets.
This description was generated via AI from an annual report. Updated about 1 year ago.